A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)
Phase: Phase I-II clinical trials
Principal Investigator: Dott.ssa Damian Silvia
Main Facility: Unità Studi Clinici di Fase 1 (Early clinical Drug Development Team-ECDD)
Drug: MK-1084, Cetuximab
Pathologies: Advanced Solid Tumours
ClinicalTrials.gov: Read the details about clinical trials
A phase II study with the aim to evaluate the safety, tolerability and efficacy of the MK-1084 administered as single agent or in combination with cetuximab in participants with KRAS G12C mutant advanced solid tumors that have progressed on or after standard systemic treatment or with no satisfactory alternative treatment options (prior KRAS inhibitor therapy excluded).
Last update: 21/04/2026